688298.SHG Zhejiang Orient Gene Biotech Co Ltd
- Market cap
- CNY 3.58B
- P/E
- -
- P/B
- 0.61x
- ROE
- -7.0%
- Dividend yield
- 0.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688298.SHG undervalued?
Graham numberThe Graham number of Zhejiang Orient Gene Biotech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Orient Gene Biotech Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Orient Gene Biotech Co Ltd yet.
Zhejiang Orient Gene Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products in China and internationally. Its products include POCT instant diagnostic reagents that are used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company also offers human and animal health products; and raw materials for rapid testing, fluorescent immunoassay, western blot, biochemistry, and molecula…
Full company profileZhejiang Orient Gene Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Orient Gene Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 182M | 224M | 286M | 367M | 3.27B | 10.2B | 8.77B | 820M | 828M | 959M | 957M |
| Gross Profit | 86.7M | 106M | 137M | 173M | 2.51B | 7.49B | 3.61B | 180M | 169M | 959M | 417M |
| Operating Income | 40.3M | 37.2M | 75.2M | 91.0M | 1.97B | 5.78B | 2.53B | -384M | -579M | -576M | -301M |
| EBITDA | 55.0M | 47.8M | 87.0M | 101M | 1.98B | 5.80B | 2.56B | -235M | -386M | -398M | -363M |
| Net Income | 35.6M | 32.7M | 65.4M | 82.1M | 1.68B | 4.92B | 2.07B | -398M | -529M | -564M | -396M |
| EPS | 0.40 | 0.22 | 0.43 | 0.54 | 8.50 | 24 | 10 | -1.97 | -2.69 | -2.93 | -1.97 |
| Balance Sheet | |||||||||||
| Total Assets | 241M | 259M | 338M | 362M | 3.57B | 8.98B | 10.7B | 9.00B | 8.09B | 7.14B | 6.80B |
| Total Liabilities | 142M | 121M | 130M | 107M | 1.12B | 2.09B | 2.38B | 1.45B | 1.30B | 1.05B | 1.04B |
| Shareholders' Equity | 98.7M | 133M | 201M | 252M | 2.45B | 6.86B | 8.16B | 7.44B | 6.65B | 5.99B | 5.68B |
| Cash & Short-term Investments | 80.8M | 77.9M | 103M | 85.4M | 2.24B | 6.27B | 7.76B | 5.22B | 3.29B | 2.45B | 2.17B |
| Total Debt | 76.0M | 56.0M | 50.0M | 27.0M | 5.22M | 18.5M | 82.2M | 608M | 164M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.8M | 33.5M | 44.3M | 54.2M | 1.79B | 5.20B | 3.00B | -1.60B | -348M | -194M | - |
| Capital Expenditure | 4.65M | 13.4M | 18.9M | 11.9M | 127M | 508M | 1.05B | 996M | 924M | 308M | 309M |
| Free Cash Flow | 7.16M | 20.2M | 25.4M | 42.3M | 1.66B | 4.70B | 1.94B | -2.64B | -1.27B | -502M | -423M |
| Ratios | |||||||||||
| ROE | 36.1% | 24.5% | 32.5% | 32.6% | 68.6% | 71.8% | 25.3% | -5.3% | -8.0% | -9.4% | -7.0% |
| ROA | 14.8% | 12.6% | 19.4% | 22.7% | 46.9% | 54.8% | 19.3% | -4.4% | -6.5% | -7.9% | -5.8% |
| Net Profit Margin | 19.5% | 14.6% | 22.9% | 22.3% | 51.4% | 48.4% | 23.6% | -48.5% | -63.9% | -58.8% | -41.4% |
| Debt to Equity | 0.77x | 0.42x | 0.25x | 0.11x | 0.00x | 0.00x | 0.01x | 0.08x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Orient Gene Biotech Co Ltd dividends
- Dividend yield
- 0.19%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 26, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 6.71M | 0.03 | - |
| 2024 | CNY 16.6M | 0.08 | - |
| 2023 | CNY 351M | 1.74 | - |
| 2022 | CNY 742M | 3.68 | 35.9% |
| 2021 | CNY 505M | 2.50 | 10.3% |
| 2020 | CNY 25.3M | 0.13 | 1.5% |
| 2019 | CNY 33.2M | 0.22 | 40.5% |
| 2018 | CNY 3.68M | 0.02 | 5.6% |
| 2017 | CNY 3.92M | 0.03 | 12.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 26, 2023.
Who owns Zhejiang Orient Gene Biotech Co Ltd
- Insiders 52.42%
- Institutions 1.27%
- Public & others 46.31%
- Shares outstanding 202M
- Free float 93.9M
Zhejiang Orient Gene Biotech Co Ltd company profile
- Company name
- Zhejiang Orient Gene Biotech Co Ltd
- Ticker
- 688298.SHG
- ISIN
- CNE100003RM8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,283
- Fiscal year end
- December
- Address
- No. 3787, East Yangguang Avenue, Huzhou, China, 313300
- Phone
- 86 57 2530 3755
- Website
- orientgene.com
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products in China and internationally. Its products include POCT instant diagnostic reagents that are used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company also offers human and animal health products; and raw materials for rapid testing, fluorescent immunoassay, western blot, biochemistry, and molecular diagnostics. It serves pharmacies chain, supermarkets, tertiary hospitals, healthcare institutions, third-party laboratories, medical distributors, and pharmaceutical distribution clients. Zhejiang Orient Gene Biotech Co., Ltd was incorporated in 2005 and is based in Huzhou, China.
Zhejiang Orient Gene Biotech Co Ltd management
10- Mr. Xiaoliang FangGM & Director · born 1957
- Mr. Shichang XiFinancial Officer · born 1974
- Ms. Ye Ping ZhangDeputy GM & Secretary · born 1979
- Ms. Pang QiDeputy General Manager · born 1967
- Mr. Jinhong YuDeputy General Manager · born 1971
- Ms. Jinfeng TanDeputy General Manager · born 1982
- Ms. Chunmei ZhongDeputy General Manager · born 1979
- Ms. Faying XuDeputy General Manager · born 1975
- Mr. Yun Ou YangDeputy General Manager · born 1976
- Yuanyuan LiAccounting Supervisor